Schedule of share-based compensation expense |
|
|
Three Months Ended June 30, (unaudited)
|
|
Six Months Ended June 30, (unaudited)
|
(in thousands)
|
|
2021
|
|
2020
|
|
2021
|
|
2020
|
General and administrative
|
|
$
|
174 |
|
$
|
219 |
|
$
|
391 |
|
$
|
290 |
Sales and marketing
|
|
|
16 |
|
|
38 |
|
|
57 |
|
|
52 |
Research and development
|
|
|
42 |
|
|
30 |
|
|
113 |
|
|
40 |
Cost of revenues
|
|
|
7 |
|
|
8 |
|
|
62 |
|
|
11 |
|
|
$
|
239 |
|
$
|
295 |
|
$
|
623 |
|
$
|
393 |
|
|
|
Year ended December 31,
|
|
|
2020
|
|
2019
|
General and administrative
|
|
$
|
444,495 |
|
$
|
256,508 |
Sales and marketing
|
|
|
126,632 |
|
|
69,856 |
Research and development
|
|
|
65,518 |
|
|
55,921 |
Cost of revenues
|
|
|
31,427 |
|
|
14,814 |
|
|
$
|
668,072 |
|
$
|
397,099 |
|
Schedule of stock option activity |
|
|
Number of Shares under Option Plan
|
|
Weighted- Average Exercise Price per Option
|
|
Weighted- Average Remaining Contractual Life (in years)
|
Outstanding at December 31, 2020
|
|
4,211,857 |
|
|
$
|
0.76 |
|
8.6 |
Granted
|
|
2,378,915 |
|
|
$
|
3.00 |
|
|
Exercised
|
|
(154,902 |
)
|
|
$
|
0.81 |
|
|
Forfeited and expired
|
|
(69,905 |
)
|
|
$
|
1.36 |
|
|
Outstanding at June 30, 2021
|
|
6,365,965 |
|
|
$
|
1.59 |
|
8.40 |
Exercisable at June 30, 2021
|
|
2,939,225 |
|
|
$
|
0.93 |
|
8.18 |
Vested and expected to vest at June 30, 2021
|
|
5,955,731 |
|
|
$
|
1.49 |
|
8.60 |
|
|
|
Number of Shares under Option Plan
|
|
Weighted-Average Exercise Price per Option
|
|
Weighted- Average Remaining Contractual Life (in years)
|
Outstanding at December 31, 2019
|
|
2,749,298 |
|
|
$
|
0.87 |
|
9.0 |
Granted
|
|
2,064,603 |
|
|
|
0.64 |
|
9.3 |
Exercised
|
|
(100,059 |
)
|
|
|
0.81 |
|
|
Forfeited and expired
|
|
(501,985 |
)
|
|
|
0.83 |
|
|
Outstanding at December 31, 2020
|
|
4,211,857 |
|
|
$
|
0.76 |
|
8.6 |
Exercisable at December 31, 2020
|
|
2,374,630 |
|
|
$
|
0.78 |
|
8.5 |
Vested and expected to vest at December 31, 2020
|
|
4,211,857 |
|
|
$
|
0.76 |
|
8.6 |
|